
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BP2202
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : BrightPath Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
BrightPath, Cellistic Collaborate on BCMA CAR-iNKT Cell Phase 1 Trial
Details : The collaboration aims to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
December 13, 2024
Lead Product(s) : BP2202
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : BrightPath Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
